Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innovus Pharmaceuticals has signed an exclusive marketing and distribution agreement to grant Denmark-based DanaLife an 18-month worldwide distribution right (excluding Canada), to market and sell its topical consumer care product Zestra.
Subscribe to our email newsletter
The product, which is used to increase female sexual arousal and desire and satisfaction, is approved for marketing in alternative markets which excludes all medical and mainstream sales channels.
In order to promote Zestra in the medical and mainstream channels, the company is currently negotiating with pharmaceutical companies.
Innovus Pharma president and CEO Bassam Damaj said Zestra is already available in the medical and mainstream channels in the US and Canadian markets and this is a good opportunity for the company to expand into additional sales channels.
"This partnership is the third of many partnerships the Company is expected to announce in the near future and opens a large untapped market for Zestra."
According to the company, initial minimum orders for the product are expected to be $250,000.
In case DanaLife meets certain minimum sales numbers, the terms of the agreement would be extended by another 18 months.
DanaLife president Jes Bech Muller said: "DanaLife performed a use study with Zestra in Denmark and achieved excellent results. We expect this product to exceed our projections.
"The alternative market for female products is very large, and is estimated to be over $2 billion according to the NY Post (April 22, 2013)."
Zestra is a patented blend of natural oils that is clinically-proven in double-blind placebo-controlled clinical trials in about 300 women to increase the arousal, desire and sexual satisfaction in FSI/AD women in a statistical significant manner.